- Home
- LEGH vs TERN Comparison
LEGH vs TERN Comparison
Compare LEGH & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- TERN
- Stock Information
- Founded
- LEGH 2005
- TERN 2017
- Country
- LEGH United States
- TERN United States
- Employees
- LEGH N/A
- TERN N/A
- Industry
- LEGH Homebuilding
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- TERN Health Care
- Exchange
- LEGH Nasdaq
- TERN Nasdaq
- Market Cap
- LEGH 646.4M
- TERN 634.5M
- IPO Year
- LEGH 2018
- TERN 2021
- Fundamental
- Price
- LEGH $27.51
- TERN $7.23
- Analyst Decision
- LEGH Strong Buy
- TERN Buy
- Analyst Count
- LEGH 1
- TERN 6
- Target Price
- LEGH $29.00
- TERN $13.99
- AVG Volume (30 Days)
- LEGH 75.6K
- TERN 1.2M
- Earning Date
- LEGH 11-11-2025
- TERN 11-11-2025
- Dividend Yield
- LEGH N/A
- TERN N/A
- EPS Growth
- LEGH 2.38
- TERN N/A
- EPS
- LEGH 2.23
- TERN N/A
- Revenue
- LEGH $184,284,000.00
- TERN N/A
- Revenue This Year
- LEGH $0.57
- TERN N/A
- Revenue Next Year
- LEGH $8.92
- TERN N/A
- P/E Ratio
- LEGH $12.33
- TERN N/A
- Revenue Growth
- LEGH 8.79
- TERN N/A
- 52 Week Low
- LEGH $21.58
- TERN $1.87
- 52 Week High
- LEGH $29.45
- TERN $11.00
- Technical
- Relative Strength Index (RSI)
- LEGH 58.86
- TERN 56.88
- Support Level
- LEGH $26.91
- TERN $6.78
- Resistance Level
- LEGH $27.75
- TERN $7.67
- Average True Range (ATR)
- LEGH 0.72
- TERN 0.44
- MACD
- LEGH -0.20
- TERN -0.04
- Stochastic Oscillator
- LEGH 29.20
- TERN 51.33
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.